Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience †

SIMPLE SUMMARY: Fulvestrant is a medication that is approved as first and second-line treatment in patients with hormone receptor positive advanced breast cancer. In clinical practice, fulvestrant is still used beyond the second line of treatment. This study investigated the use of fulvestrant in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrahennadi, Samitha, Sami, Amer, Haider, Kamal, Chalchal, Haji Ibraheem, Le, Duc, Ahmed, Osama, Manna, Mita, El-Gayed, Ali, Wright, Philip, Ahmed, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391338/
https://www.ncbi.nlm.nih.gov/pubmed/34439317
http://dx.doi.org/10.3390/cancers13164163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391338/
https://www.ncbi.nlm.nih.gov/pubmed/34439317
http://dx.doi.org/10.3390/cancers13164163

Ejemplares similares